Another day, another sharp selloff for a biotech company that recently merged with a blank-check company.
On Friday, shares of Greenlight Biosciences Holdings fell more than 16 percent. The company, which develops RNA products for agriculture and human health, went public February 4 after completing its merger with SPAC Environmental Impact Acquisition Corp.
